Wockhardt shares soar over 17% to 52-week high as CDSCO grants authorisation for UTI antibiotic

At around 12 PM, the stock was trading 16.43% higher at ₹291 per equity share. The scrip touched a year’s low of ₹1,086.70 apiece on March 23, 2026.

The share has gained 31% in the past week and 48% over the month. On a year-to-date basis, it has advanced 45%.

In a regulatory filing dated May 28, the company said that it received authorisation from the Indian drug regulatory authority for the import and marketing of its “indigenously discovered and developed, first-in-class breakthrough” antibiotic, Zaynich (Zidebactam/Cefepime), in India.

The approval, Wockhardt stated, is for the treatment of adult patients (18 years and above) with complicated urinary tract infections (cUTI), including pyelonephritis, as well as cases with concurrent Gram-negative bacteremia.

“The approval is supported by results from the pivotal ENHANCE-1 study (NCT04979806), a multinational, randomised, double-blind Phase 3 clinical trial evaluating the efficacy and safety of Zaynich compared with meropenem in patients with cUTI, including pyelonephritis,” it added.

Wockhardt has submitted a New Drug Application (NDA) in the United States and a Marketing Authorisation Application (MAA) in the European Union for Cefepime/Zidebactam, and they are currently under regulatory review.

Zaynich, an injectable antibiotic, has also received priority review, fast track and qualified infectious disease product (QIDP) designations by the United States Food and Drug Administration (US FDA) for complicated urinary tract Infections (cUTI), complicated intra-abdominal infections (cIAI), hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP).

Wockhardt Q4 results

The company recorded a consolidated net profit of ₹166 crore in the March quarter of the 2025-26 financial year (Q4 FY26), compared to a loss of ₹25 crore in the fourth quarter of the 2024-25 fiscal year (Q4 FY25).

The pharmaceutical and biotechnology major’s revenue from operations soared 30% year-on-year (YoY) to ₹965 crore during the quarter under review, as against ₹743 crore in the year-ago period.

At an operational level, its EBITDA (earnings before interest, tax, depreciation and amortisation) stood at ₹196 crore for the reporting quarter, marking a 147% YoY surge from ₹79 crore in Q4 FY25.

Wockhardt has a total market capitalisation of ₹32,948.54 crore as of May 29, 2026, according to data on the NSE.